1. Pink Sheet
  2. >>Compliance

For Effient And Brilinta, A Formidable Competitor Grows More So

 
• By Jessica Merrill

Plavix was a tough competitor before it went generic; now that cheap versions of the clot-buster are available, the market will prove even more challenging for the remaining branded antiplatelet drugs.

Eli Lilly & Co./Daiichi Sankyo Co. Ltd.’s Effient (prasugrel) and AstraZeneca PLC’s Brilinta (ticagrelor) faced a formidable competitor when Bristol-Myers Squibb Co./Sanofi’s Plavix (clopidogrel) was still an exclusive brand. But now that generic versions of the market-leading clot-buster clopidogrel are available in the U.S. for about $1 per day, the two branded oral antiplatelet drugs will face an even harsher commercial environment as payers try to drive use of generics over brands.

The availability of generic Plavix could stunt Effient’s recent growth and halt Brilinta’s launch before it even starts. Multiple versions of Plavix, which is used for acute coronary syndrome patients, were approved by FDA May 17

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Marketing & Advertising

More from Compliance

Pharma Industry Argues Tax, Other Incentives Better Than Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a federal 232 investigation.

US FDA Expands Surprise Foreign Inspections But Loses Associate Commissioner Michael Rogers

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.

Pharma Predicts Modest Tariff Impact, Depending On What Comes Next

 
• By Jessica Merrill

Drugmakers are not expecting a big financial hit from tariffs for now, but a report commissioned by the industry trade association PhRMA suggests a potentially steep cost for pharma-sector tariffs.